Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Aug 29;373(3):341-4.
doi: 10.1016/j.bbrc.2008.06.048. Epub 2008 Jun 23.

Sirtuins: Novel Targets for Metabolic Disease in Drug Development


Sirtuins: Novel Targets for Metabolic Disease in Drug Development

Wei-jian Jiang. Biochem Biophys Res Commun. .


Calorie restriction extends lifespan and produces a metabolic profile desirable for treating diseases such as type 2 diabetes. SIRT1, an NAD(+)-dependent deacetylase, is a principal modulator of pathways downstream of calorie restriction that produces beneficial effects on glucose homeostasis and insulin sensitivity. Activation of SIRT1 leads to enhanced activity of multiple proteins, including peroxisome proliferator-activated receptor coactivator-1alpha (PGC-1alpha) and FOXO which helps to mediate some of the in vitro and in vivo effects of sirtuins. Resveratrol, a polyphenolic SIRT1 activator, mimics the effects of calorie restriction in lower organisms and in mice fed a high-fat diet ameliorates insulin resistance. In this review, we summarize recent research advances in unveiling the molecular mechanisms that underpin sirtuin as therapeutic candidates and discuss the possibility of using resveratrol as potential drug for treatment of diabetes.

Similar articles

  • Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
    Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bemis JE, Xie R, Disch JS, Ng PY, Nunes JJ, Lynch AV, Yang H, Galonek H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, Westphal CH. Milne JC, et al. Nature. 2007 Nov 29;450(7170):712-6. doi: 10.1038/nature06261. Nature. 2007. PMID: 18046409 Free PMC article.
  • Sirtuins: novel targets for metabolic disease.
    Elliott PJ, Jirousek M. Elliott PJ, et al. Curr Opin Investig Drugs. 2008 Apr;9(4):371-8. Curr Opin Investig Drugs. 2008. PMID: 18393104 Review.
  • Metabolic benefits from Sirt1 and Sirt1 activators.
    Chaudhary N, Pfluger PT. Chaudhary N, et al. Curr Opin Clin Nutr Metab Care. 2009 Jul;12(4):431-7. doi: 10.1097/MCO.0b013e32832cdaae. Curr Opin Clin Nutr Metab Care. 2009. PMID: 19474719 Review.
  • Sirtuin activators.
    Alcaín FJ, Villalba JM. Alcaín FJ, et al. Expert Opin Ther Pat. 2009 Apr;19(4):403-14. doi: 10.1517/13543770902762893. Expert Opin Ther Pat. 2009. PMID: 19441923 Review.
  • Calorie restriction--the SIR2 connection.
    Guarente L, Picard F. Guarente L, et al. Cell. 2005 Feb 25;120(4):473-82. doi: 10.1016/j.cell.2005.01.029. Cell. 2005. PMID: 15734680 Review.
See all similar articles

Cited by 26 articles

See all "Cited by" articles

LinkOut - more resources